An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial

BACKGROUND: Bubonic plague is the primary manifestation of infection with Yersinia pestis, accounting for 90% of all plague cases and with 75% of global cases reported in Madagascar. All drugs in use for treating plague are registered based on experimental data and anecdotal evidence, and no regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Randremanana, Rindra Vatosoa, Raberahona, Mihaja, Randria, Mamy Jean de Dieu, Rajerison, Minoarisoa, Andrianaivoarimanana, Voahangy, Legrand, Agathe, Rasoanaivo, Tsinjo Fehizoro, Randriamparany, Ravaka, Mayouya-Gamana, Théodora, Mangahasimbola, Reziky, Bourner, Josie, Salam, Alex, Gillesen, Annelies, Edwards, Tansy, Schoenhals, Matthieu, Baril, Laurence, Horby, Peter, Olliaro, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429934/
https://www.ncbi.nlm.nih.gov/pubmed/32807214
http://dx.doi.org/10.1186/s13063-020-04642-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429934/
https://www.ncbi.nlm.nih.gov/pubmed/32807214
http://dx.doi.org/10.1186/s13063-020-04642-2

Ejemplares similares